Ken Cacciatore
Stock Analyst at TD Cowen
(0.33)
# 4,334
Out of 5,111 analysts
12
Total ratings
30%
Success rate
-28.61%
Average return
Main Sectors:
Stocks Rated by Ken Cacciatore
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARQT Arcutis Biotherapeutics | Maintains: Outperform | $65 → $50 | $28.95 | +72.71% | 2 | Aug 9, 2023 | |
| BHC Bausch Health Companies | Downgrades: Market Perform | n/a | $6.91 | - | 1 | Jun 16, 2023 | |
| TAK Takeda Pharmaceutical Company | Maintains: Outperform | $30 → $20 | $14.61 | +36.89% | 4 | May 16, 2023 | |
| BLCO Bausch + Lomb | Initiates: Outperform | $35 | $17.09 | +104.80% | 1 | May 11, 2022 | |
| MOLN Molecular Partners AG | Initiates: Outperform | $50 | $4.09 | +1,123.99% | 1 | Jul 13, 2021 | |
| TARA Protara Therapeutics | Initiates: Outperform | $50 | $5.50 | +809.09% | 1 | Oct 19, 2020 | |
| BHVN Biohaven | Initiates: Outperform | $45 | $11.28 | +298.94% | 1 | Apr 17, 2020 | |
| AMRN Amarin Corporation | Initiates: Outperform | $460 | $14.14 | +3,153.18% | 1 | Mar 2, 2020 |
Arcutis Biotherapeutics
Aug 9, 2023
Maintains: Outperform
Price Target: $65 → $50
Current: $28.95
Upside: +72.71%
Bausch Health Companies
Jun 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $6.91
Upside: -
Takeda Pharmaceutical Company
May 16, 2023
Maintains: Outperform
Price Target: $30 → $20
Current: $14.61
Upside: +36.89%
Bausch + Lomb
May 11, 2022
Initiates: Outperform
Price Target: $35
Current: $17.09
Upside: +104.80%
Molecular Partners AG
Jul 13, 2021
Initiates: Outperform
Price Target: $50
Current: $4.09
Upside: +1,123.99%
Protara Therapeutics
Oct 19, 2020
Initiates: Outperform
Price Target: $50
Current: $5.50
Upside: +809.09%
Biohaven
Apr 17, 2020
Initiates: Outperform
Price Target: $45
Current: $11.28
Upside: +298.94%
Amarin Corporation
Mar 2, 2020
Initiates: Outperform
Price Target: $460
Current: $14.14
Upside: +3,153.18%